Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 04, 2015 1:54 AM ET

Biotechnology

Company Overview of Intercept Pharmaceuticals, Inc.

Company Overview

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. It primarily develops obeticholic acid (OCA), a bile acid analog that completed Phase III clinical trial for the treatment of primary biliary cirrhosis; is in Phase III clinical trial for the treatment of nonalcoholic steatohepatitis; is in Phase 2 clinical trial for primary sclerosing cholangitis; and is in Phase I clinical trial for the treatment of biliary atresia. The company’s product candidates in preclinical stage include INT-767, a...

450 West 15th Street

Suite 505

Floor 5

New York, NY 10011

United States

Founded in 2002

203 Employees

Phone:

646-747-1000

Fax:

646-747-1001

Key Executives for Intercept Pharmaceuticals, Inc.

Founder, Chief Executive Officer, President and Director
Age: 47
Total Annual Compensation: $934.0K
Chief Financial Officer, Treasurer and Secretary
Age: 50
Total Annual Compensation: $556.9K
Chief Medical Officer and Executive Vice President of Development
Age: 61
Total Annual Compensation: $626.5K
Compensation as of Fiscal Year 2013.

Intercept Pharmaceuticals, Inc. Key Developments

FDA Grants Priority Review for Intercept Pharmaceuticals, Inc.'s Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis

Intercept Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application and granted Priority Review for obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBC). OCA is being developed to treat PBC patients with an inadequate therapeutic response to, or who are unable to tolerate, ursodeoxycholic acid (UDCA), the only drug currently approved to treat PBC. The FDA has set a target date of February 29, 2016 to take action under the Prescription Drug User Fee Act. The FDA grants Priority Review to medicines that, if approved, would be a significant improvement in the safety or effectiveness of treatment, prevention or diagnosis of serious diseases. A priority review designation means FDA's goal is to take action on the marketing application within six months of acceptance as compared to 10 months under standard review. OCA was previously granted Fast Track designation by FDA. A drug development program with Fast Track designation is afforded greater access to FDA for the purpose of expediting the drug's development, review and potential approval.

Intercept Pharmaceuticals, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Intercept Pharmaceuticals, Inc. announced consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported licensing revenue of $445,000 compared to $445,000 a year ago. Net loss was $47,894,000 or $1.99 per diluted share compared to net income of $33,470,000 or $1.51 per diluted share a year ago. For the six months, the company reported licensing revenue of $1,891,000 compared to $851,000 a year ago. Net loss was $87,280,000 or $3.78 per basic and diluted share compared to $212,559,000 or $10.50 per basic and diluted share a year ago.

Intercept Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 05, 2015

Intercept Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 05, 2015

Similar Private Companies By Industry

Company Name Region
Plectix BioSystems, Inc. United States
Algisys, LLC United States
RuiYi Inc. United States
Tissue Genesis, Inc. United States
Celexion, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Intercept Pharmaceuticals, Inc., please visit www.interceptpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.